iiinova — where your digital self keeps evolving

Freja Kirsebom @freja-kirsebom.bsky.social · 23/12/2024

Job opportunity at UKHSA - we are looking for 2 epidemiologists to join the respiratory virus section in the Immunisations division. Link to apply below & happy to chat. www.civilservicejobs.service.gov.uk/csr/index.cg...

civilservicejobs.service.gov.uk

Senior Scientist - Civil Service Jobs - GOV.UKGOV.UK

Search and apply for jobs in the UK Civil Service

121

Freja Kirsebom @freja-kirsebom.bsky.social · 11/12/2024

Our study on the effectiveness of the COVID-19 vaccines in preventing disease in pregnant women and their infants is now published in BMJ Medicine. bmjmedicine.bmj.com/content/3/1/e00…

48328

Freja Kirsebom @freja-kirsebom.bsky.social · 18/10/2023

FluSurvey is one of @UKHSA's systems for monitoring respiratory infections. It is a critical tool which helps us better understand infection and illness in the community. Sign up to take part! flusurvey.net/en (for UK residents only)

010

Freja Kirsebom @freja-kirsebom.bsky.social · 02/10/2023

First real-world data on the vaccine effectiveness (VE) of the Sanofi booster now out. TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+. www.medrxiv.org/content/10.1101/20...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 08/08/2023

In our latest pre-print we estimate vaccine effectiveness (VE) against hospitalisation and disease severity for BQ.1, CH.1.1. and XBB.1.5. TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity. www.medrxiv.org/content/10.1101/20...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 07/08/2023

Exciting opportunity - looking for a motivated senior epidemiologist for a permanent position in my team. Salary: £40,867-£45,998 Closes: 20 Aug 2023 Please R/T. Happy to chat with anyone looking to apply. www.jobs.nhs.uk/candidate/jobadvert… @pubhealthjobsuk @IDDjobs @P...

000

Freja Kirsebom @freja-kirsebom.bsky.social · 22/06/2023

Great news for RSV prevention in England! The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults. www.gov.uk/government/publications/…...

000

Freja Kirsebom @freja-kirsebom.bsky.social · 16/04/2023

Great to present our latest work today at #ECCMID2023

010

Freja Kirsebom @freja-kirsebom.bsky.social · 15/04/2023

Very excited to be in Copenhagen for #ECCMID23! I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5. Come say hi! ☺️

010

Freja Kirsebom @freja-kirsebom.bsky.social · 02/04/2023

Now out as a pre-print - our latest data on the long term duration of protection of the monovalent COVID-19 vaccines, and vaccine effectiveness (VE) of the bivalent booster vaccines against hospitalisation in England. www.medrxiv.org/content/10.1101/202…

100

Freja Kirsebom @freja-kirsebom.bsky.social · 11/01/2023

Our paper on the effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England has been featured in the Editors' Highlights of @NatureComms 👇 www.nature.com/collections/jcbdhegi…

000

Freja Kirsebom @freja-kirsebom.bsky.social · 13/12/2022

Our paper on the effectiveness of the AstraZeneca (AZ; ChAdOx1-S) vaccine when used as a booster is now peer-reviewed and out www.nature.com/articles/s41467-022-…

000

Freja Kirsebom @freja-kirsebom.bsky.social · 08/12/2022

Vaccine effectiveness (VE) of the bivalent booster vaccines against COVID-19 hospitalisation in England -> first data now out in the UKHSA vaccine surveillance report 1/7 assets.publishing.service.gov.uk/go…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 02/09/2022

Our latest pre-print where we estimate vaccine effectiveness (VE) against hospitalisation following infection with the Omicron sub-lineages BA.4 and BA.5 in England is now up: www.medrxiv.org/content/10.1101/202…

100

Freja Kirsebom @freja-kirsebom.bsky.social · 25/05/2022

Now peer-reviewed and published @TheLancetInfDis, our study on vaccine effectiveness (VE) against symptomatic disease and hospitalisation for BA.2 compared to BA.1. www.thelancet.com/journals/laninf/a…

100

Freja Kirsebom @freja-kirsebom.bsky.social · 28/04/2022

The first real-world data on the vaccine effectiveness (VE) of the AstraZeneca booster against symptomatic disease and hospitalisation with Delta and Omicron - new pre-print from us this week. khub.net/documents/135939561/338928…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 25/03/2022

Pre-print of our study investigating vaccine effectiveness (VE) against symptomatic disease caused by the Omicron sub-lineage BA.2 is out on medRxiv today www.medrxiv.org/content/10.1101/202…

100

Freja Kirsebom @freja-kirsebom.bsky.social · 24/03/2022

Our most comprehensive analysis so far on the protection conferred by vaccines against hospitalisation over time is published today in the UKHSA Vaccine Surveillance report assets.publishing.service.gov.uk/go…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 03/03/2022

Our peer-reviewed paper estimating vaccine effectiveness against symptomatic disease with Omicron is now out! www.nejm.org/doi/full/10.1056/NEJMo…

000

Freja Kirsebom @freja-kirsebom.bsky.social · 09/02/2022

Great to see a little paper from my PhD has been selected for the @SciReports Editor's Choice Negative Results Collection. www.nature.com/collections/gcifjeba…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 27/01/2022

Two important updates from our team this week: - Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged - VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster 1/7 Full report assets.publishing.service.gov.uk/g...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 14/01/2022

This week's updated analysis from our team on vaccine effectiveness against Omicron infection is now published in the UKHSA Technical Briefing. Good news - protection from the boosters against severe disease continues to be well maintained. assets.publishing.service.gov.uk/go…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 31/12/2021

This week, we were able to estimate vaccine effectiveness (VE) against hospitalisation for the first time. In short, good news. VE after a booster is close to 90%. The full update from our team is published in this week's technical briefing update: assets.publishing.service.gov.uk/go…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 23/12/2021

An update from our team on the latest vaccine effectiveness (VE) estimates against symptomatic infection with the Omicron variant has now been published in the UKHSA Variant Technical Briefing 33 (page 24). assets.publishing.service.gov.uk/go…...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 10/12/2021

Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses. More below 👇 1/11

100

Freja Kirsebom @freja-kirsebom.bsky.social · 23/03/2021

Great to be able to share our review on the role of neutrophils during respiratory viral infections, with @cjohansson_lab. Now out 👉https://doi.org/10.1038/s41385-021-00397-4

000

Freja Kirsebom @freja-kirsebom.bsky.social · 26/01/2020

Second paper of my PhD is out! 🥳 A small but important study (we think🙂) on some things we noticed, with surprise, that neutrophils *don't* do during RSV infection. With great thanks to everyone involved, especially Christina, Marina & @cjohansson_lab www.nature.com/articles/s41598-0...

100

Freja Kirsebom @freja-kirsebom.bsky.social · 06/03/2019

Really enjoyed presenting my data on the signalling pathways regulating neutrophil recruitment and activation in RSV infection last week at the UK-Russia Young Medics Association conference @SechenovUni. Thanks for inviting me!

000